ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results

SAN DIEGO, Sept. 13, 2011 /PRNewswire/ -- RESMED INC. (NYSE: RMD), announced today that on Monday, October 24, 2011, it will release its results for the first quarter of fiscal year 2012, ended September 30, 2011. A press release with ResMed's results will be issued after 1:00 p.m. Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook.

(Logo: https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

The conference call is scheduled to begin at 1:30 p.m. Pacific Time and will be webcast on ResMed's website at http://investor.resmed.com.  Please go to this section of the website 5-10 minutes prior to the call and click on the icon for the "Q1 2012 results webcast". The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:




   9:30 p.m.

London

   7:30 a.m.

Sydney, Australia (October 25, 2011)



TO PARTICIPATE in the conference call, please call one of the numbers below at least 10 minutes before the call begins and identify yourself to the operator:



US:      

617-801-9715

Outside US:  

+1 617-801-9715

Conference Name:  

Q1 2012 ResMed Inc. Results Conference Call  

Participant Passcode:

99214751



The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:



US:

617-801-6888

Outside US:    

+1 617-801-6888

Passcode:

92613651



ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. Further information can be obtained by contacting Constance Bienfait at ResMed Inc. at +1 (858) 836-5971, or by visiting the company's website at www.resmed.com.

SOURCE ResMed Inc.